Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,854
datasets available to search
ShareScore release 0.9.0
Dataset results
2,854 results for “hepatocellular carcinoma”
Dataset related to article "Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance."
<p>I</p> <p>NTRODUCTION AND AIM:</p> <p>The American Association for the Study of the Liver (AASLD) recommends contrast computerized tomography (CT-scan) and magnetic resonance (MRI) to diagnose hepatocellular carcinoma (HCC) arising in cirrhotic patients under semiannual surveillance with abdominal ultrasound (US). A US guided fine needle biopsy (FNB) serves the same purpose in radiologically undiagnosed tumors and incidentally detected nodules in cirrhotics outside surveillance. In this population, we evaluated the performance of radiological diagnosis of HCC according to 2010 AASLD recommendations.</p> <p>MATERIALS AND METHODS:</p> <p>All cirrhotic patients with a liver nodule incidentally detected by US were prospectively investigated with a sequential application of CT-scan/MRI examination and a FNB.</p> <p>RESULTS:</p> <p>Between 2011 and 2015, 94 patients (mean age 67 years) had a liver nodule (total 120) detected by US in the context of histologically confirmed cirrhosis. Mean nodules diameter was 40 (10-160) mm, 87 (73%) <5cm. At histology, 84 (70%) nodules were HCC, 8 (7%) intrahepatic cholangiocarcinoma, 6 (5%) metastases, 2 (2%) neuroendocrine tumors and 20 (16%) benign lesions. Hyperenhancement in arterial phase followed by wash-out in venous phases on at least one radiological technique was demonstrated in 62 nodules (61 HCC, 1 high grade dysplastic nodule), with a specificity of 97% (IC95%: 85-100%), sensitivity 73% (IC95%: 62-81%) and diagnostic accuracy 80%, being 64% for ≥5cm HCC. Sensitivity of AFP >200ng/mL was 12% (IC95%: 6-23%).</p> <p>CONCLUSION:</p> <p>A single contrast imaging technique showing a typical contrast pattern confidently identifies HCC also in cirrhotic patients with an incidental liver nodule, thereby reducing the need for FNB examinations.</p>
Dataset related to article"Integrating single-cell and spatial transcriptomics to elucidate the crosstalk between cancer-associated fibroblasts and cancer cells in hepatocellular carcinoma with spleen-deficiency syndrome"
<p>Most patients with hepatocellular carcinoma (HCC) in China have been diagnosed with spleen deficiency syndrome (SDS), which accelerates the progression of HCC by disrupting the tumor microenvironment (TME) homeostasis. However, the underlying mechanism remains to be explored. By integrating single-cell and spatial transcriptomics, we found that the crosstalk between CAFs and cancer cells is crucial for the tumor-promoting effect of SDS. CAFs recruited by HCC via PDGFA may lead to ECM remodeling through activation of the TGF-β pathway, thereby forming a physical barrier to block immune cell infiltration under SDS. </p>
Dataset related to article "Charlson comorbidity index and G8 in older old adult(≥80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy "
<p>This record contains raw data related to article “Charlson comorbidity index and G8 in older old adult(≥80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy"</p> <p><strong>Introduction: </strong> Hepatocellular Carcinoma (HCC) is characterized, in Western countries, by higher incidence and mortality rates in the older adult population. In frail patients, limited therapeutic resources are available due to limited expected benefit concerning the risk of treatment-related toxicity. The aim of our study is to evaluate the role of Stereotactic Body Radiotherapy (SBRT) in the clinical management of older old adults (age ≥ 80 years) HCC patients and to identify predictors of efficacy and toxicity.</p> <p><strong>Material and methods: </strong> Clinical and treatment-related data of older old adults HCC patients treated with SBRT at our institution were retrospectively reviewed. Statistical analysis was carried out to identify variables correlated with impaired outcome and toxicity.</p> <p><strong>Results: </strong> Forty-two patients were included, accounting for 63 treated tumors. Median age was 85 (range 80-91) years. Median Charlson Comorbidity Index (CCI) and G8 scores were 10 (range 7-16) and 11 (range 8-14), respectively. SBRT was administered to a median BED10 of 103 Gy10. Median follow-up interval was 11 (range 3-40) months. Two years Local Control (LC), Progression-Free Survival (PFS), and Overall Survival (OS) were 93%, 31%, and 43%, respectively. Acute toxicity occurred in 28% (n = 13) of treatments. A G8 score > 10 was associated with improved survival (p = 0.045), while a CCI ≥10 was correlated with increased acute toxicity (p = 0.021).</p> <p><strong>Conclusions: </strong> SBRT is a safe and effective option in older old adults HCC patients. A comprehensive geriatric assessment (CGA) is advised before treatment decisions to select optimal candidates for SBRT.</p>
Dataset related to article "Phenotypic and molecular changes in nodule-in-nodule hepatocellular carcinoma with pathogenetic implications"
<p>This record contains raw data related to article "Phenotypic and molecular changes in nodule-in-nodule hepatocellular carcinoma with pathogenetic implications"</p> <p>AIMS:</p> <p>Nodule-in-nodule (N/N) hepatocellular carcinoma (HCC) is a convincing proof of multistep hepatocarcinogenesis. In this lesion, an inner HCC develops within an outer, more differentiated, tumour, which can be rapidly taken over by the former so that N/N HCC is rarely detected.</p> <p>METHODS AND RESULTS:</p> <p>Ten resected N/N HCCs arising in cirrhotic background and characterized: (i) as outer lesions by early (n = 3) and G1 (n = 7) HCC; (ii) as inner lesions by G1 (n = 3) and G2 (n = 7) HCC. The largest/smallest diameters of outer and inner nodules were, respectively, 20/6 mm and 16/4 mm. We investigated vascular (CD34 and endocan), hepatocellular VEGF, GS, GPC3, HSP70 and CHC) and molecular (TERT promoter and β-catenin) changes taking place from the outer neoplastic compartment to the inner neoplastic compartment (INC). A diffuse pattern of CD34+ capillarized vessels and focal endocan immunoreactivity were major distinctive features acquired in the INC; VEGF immunoreactivity was inversely related to CD34 staining. A gain in the number of cells immunoreactive for GPC3, HSP70, and CHC, but not of GS-immunoreactive cells, also occurred in the INC. TERT promoter mutations were seen in half of the cases in both compartments, whereas β-catenin mutations were more rarely detectable.</p> <p>CONCLUSIONS:</p> <p>Major phenotypic changes take place in the INC of N/N HCC. TERT promoter mutations take place frequently and very early, and, in contrast to β-catenin mutations, do not appear to be acquired during N/N growth. These findings suggest that inner nodules represent a step further along the pathway of tumour progression, in contrast to earlier, simply initiated, lesions, and that complete neovascularisation predicts a change in HCC biology.</p>
Hepatocellular Carcinoma incidences and risk factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents
<p><span>Table S1: </span><span>Comparisons of baseline clinical characteristics between patients treated with DAA and IFN after propensity score matching.</span></p> <p><span>Table S2: </span><span>Univariate and multivariate cox regression model for HCC after propensity score matching</span><span>.</span></p> <p><span>Table S3: </span><span>Univariate and multivariate cox regression model for early HCC (<3 years)</span><span>.</span></p> <p><span>Table S4: </span><span>Univariate and multivariate cox regression model for late HCC (3-6 years)</span><span>. </span></p> <p><span>Figure S1: Flowchart of patient recruitment.</span></p> <p><span>Figure S2: Scheme for time scale in Cox regression analysis to investigate early HCC and late HCC predictors.</span></p> <p><span>Figure S3: The cumulative HCC incidences stratified by age </span><span><span>³</span></span><span>60 and <60 years</span><span> (A) in ACLD (B) in non-ACLD</span></p> <p><span>Figure S4: The comparisons of the HCC risks within 3 years (early onset) and after 3 years (late onset). (A) DAA group (B) IFN group. </span></p>
Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma
ClinicalTrials.gov study NCT05344664. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
ClinicalTrials.gov study NCT02082691. IPD Sharing: Not stated. Countries: 0. Publications: 0.
East-West Hepatocellular Carcinoma Study Group
ClinicalTrials.gov study NCT01237132. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
ClinicalTrials.gov study NCT01076517. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Integration of epigenomic and transcriptomic profiling uncovers EZH2 target genes linked to cysteine metabolism in hepatocellular carcinoma
GEO Series GSE237952. Homo sapiens. 24 samples. Type: Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing.
Chip-chip from Hepatocellular carcinoma (HCC) specimens with H3K4me3
GEO Series GSE52190. Homo sapiens. 6 samples. Type: Genome binding/occupancy profiling by genome tiling array.
PHAROH lncRNA regulates c-Myc translation in hepatocellular carcinoma via sequestering TIAR
GEO Series GSE167316. Mus musculus. 4 samples. Type: Expression profiling by array.
Genome-wide DNA methylation profiles of liver tissue samples obtained from patients with metabolic dysfunction-associated steatohepatitis (MASH), with or without hepatocellular carcinoma
GEO Series GSE304513. Homo sapiens. 41 samples. Type: Methylation profiling by genome tiling array.
CircETFA Upregulates CCL5 by Sponging miR-612 and Recruiting EIF4A3 to Promote Hepatocellular Carcinoma
GEO Series GSE166678. Homo sapiens. 6 samples. Type: Non-coding RNA profiling by array.
Up-regulated aldo-ketoreductase1B10 in chronic hepatitis C: Association with serum alpha-fetoprotein and hepatocellular carcinoma
GEO Series GSE32221. Homo sapiens. 48 samples. Type: Expression profiling by array.
Amentoflavone induces cell autophagy through promoting phosphorylation of ULK1 in hepatocellular carcinoma
GEO Series GSE221340. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
Diwu Yanggan capcules alleviate hepatocellular carcinoma progression by regulating YAP signaling
GEO Series GSE297952. Mus musculus. 8 samples. Type: Expression profiling by high throughput sequencing.
Inhibition of EZH2 restores normal expression of genes associated with cysteine metabolism and ferroptosis in hepatocellular carcinoma [RNA-seq]
GEO Series GSE237951. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
Persistent microRNA-gene networks in primary human hepatocytes upon withdrawal of aflatoxin B1 exposure are related to hepatocellular carcinoma [miRNA]
GEO Series GSE71540. Homo sapiens. 6 samples. Type: Non-coding RNA profiling by array.
Small RNAs expression of three hepatocellular carcinoma cell lines with different organ-tropism.
GEO Series GSE39003. Homo sapiens. 3 samples. Type: Non-coding RNA profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.